AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33051340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with low PD-L1 expression
Number of subjects: 100
Study 33051340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab without low PD-L1 expression
Number of subjects: 100
Study 33372218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (CDA) using the Mobi-C® Cervical Disc
Number of subjects: 0
Study 32100496 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with lifestyle control
Number of subjects: 90
Study 32100496 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle control
Number of subjects: 90
Study 35397527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review
Number of subjects: 211
Study 35397527 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 211
Study 34600562 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory T cells plus standard of care (SoC)
Number of subjects: 182
Study 34600562 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) cells plus standard of care (SoC)
Number of subjects: 182
Study 34600562 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 182
Study 32838470 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K dependent oral anticoagulants (NOACs)
Number of subjects: 0
Study 32838470 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion
Number of subjects: 0
Study 32838470 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 0
Study 33677049 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-lung low-dose radiation therapy (LDRT) 1 Gy
Number of subjects: 22
Study 33677049 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation (sham-RT)
Number of subjects: 22
Study 33677049 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-lung low-dose radiation therapy (LDRT)
Number of subjects: 22
Study 32067817 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine from Institute of Medical Biology Chinese Academy of Medical Sciences (CAMS) for the first dose and Sinovac vaccine for the second dose (Group D)
Number of subjects: 300
Study 32067817 — intervention group
Group type: COMPARATOR
Intervention: Single vaccine from one manufacturer (two groups)
Number of subjects: 300
Study 32067817 — intervention group
Group type: COMPARATOR
Intervention: Mixed schedules using vaccines from two manufacturers (two groups)
Number of subjects: 300
Study 32783199 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed participants
Number of subjects: 986
Study 32783199 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious participants
Number of subjects: 986
Study 35271378 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth backgrounds (six different virtual backgrounds)
Number of subjects: 0
Study 36333741 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible charrière‐4 feeding tube inserted using Magill forceps (group 1)
Number of subjects: 31
Study 36333741 — intervention group
Group type: COMPARATOR
Intervention: Both groups (group 1 and group 2)
Number of subjects: 31
Study 32976633 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent supportive housing (PSH)
Number of subjects: 423
Study 32976633 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 423
Study 35446282 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Training (CPX)
Number of subjects: 10
Study 35446282 — intervention group
Group type: COMPARATOR
Intervention: Compound Training (CPD)
Number of subjects: 10
Study 36045387 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based Unified Protocol (iUP)
Number of subjects: 120
Study 36045387 — intervention group
Group type: COMPARATOR
Intervention: enhanced waiting list control (eWLC)
Number of subjects: 120
Study 32334292 — intervention group
Group type: EXPERIMENTAL
Intervention: USG FICB (fascia iliaca compartment block)
Number of subjects: 182
Study 32334292 — intervention group
Group type: COMPARATOR
Intervention: Sham FICB (control group)
Number of subjects: 182
Study 36184755 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 0
Study 33693461 — intervention group
Group type: EXPERIMENTAL
Intervention: HADM (Human Acellular Dermal Matrix)
Number of subjects: 68
Study 33693461 — intervention group
Group type: COMPARATOR
Intervention: BADM (Bovine Acellular Dermal Matrix)
Number of subjects: 68
Study 33693461 — intervention group
Group type: EXPERIMENTAL
Intervention: HADM
Number of subjects: 68
Study 33693461 — intervention group
Group type: COMPARATOR
Intervention: BADM
Number of subjects: 68
Study 32268344 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of levodopa
Number of subjects: 0
Study 32268344 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg of haloperidol
Number of subjects: 0
Study 32268344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35288419 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Number of subjects: 0
Study 35288419 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated and uninfected)
Number of subjects: 0
Study 34187530 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV (Vt = 6 ml/kg of ideal body weight, respiratory rate initially set at 16 breaths/min, PEEP at 5 cmH2O, recruitment manoeuvre applied)
Number of subjects: 60
Study 34187530 — intervention group
Group type: COMPARATOR
Intervention: Control (Vt = 10 ml/kg of ideal body weight, respiratory rate initially set at 6–8 breaths/min, no PEEP, no recruitment manoeuvre)
Number of subjects: 60
Study 34187530 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV
Number of subjects: 60
Study 34187530 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 32838798 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing technology with 3D chest CT reconstruction (Group A)
Number of subjects: 89
Study 32838798 — intervention group
Group type: COMPARATOR
Intervention: Chest CT scans with image enhancement for 3D reconstruction (Group B)
Number of subjects: 89
Study 33487255 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (650 mg DHA, 3 times/week, post-HD session)
Number of subjects: 52
Study 32507538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 4,000 IU or 7,000 IU daily for 6 and 12 weeks
Number of subjects: 44
Study 34397393 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based warfarin management
Number of subjects: 721
Study 34397393 — intervention group
Group type: COMPARATOR
Intervention: Conventional warfarin management
Number of subjects: 721
Study 32012841 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise program (60 min sessions, 3 times per week for 17 weeks)
Number of subjects: 129
Study 32012841 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight at the start of pregnancy
Number of subjects: 129
Study 32012841 — intervention group
Group type: COMPARATOR
Intervention: Overweight/obesity
Number of subjects: 129
Study 36120775 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 120
Study 36120775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33650977 — intervention group
Group type: EXPERIMENTAL
Intervention: Heali mobile app and educational materials
Number of subjects: 58
Study 33650977 — intervention group
Group type: COMPARATOR
Intervention: Educational materials
Number of subjects: 58
Study 35710572 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous boost COVID‐19 vaccine regimens (intervention groups 1–4)
Number of subjects: 600
Study 35710572 — intervention group
Group type: COMPARATOR
Intervention: Homologous boost regimen (control arm)
Number of subjects: 600
Study 35710572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 600
Study 32721007 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogen (CEE) alone
Number of subjects: 27347
Study 32721007 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogen (CEE) plus 2.5 mg/d of medroxyprogesterone acetate (MPA)
Number of subjects: 27347
Study 32721007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27347
Study 35489363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (oral 20 mg per day) plus Pembrolizumab (intravenous 200 mg every 21 days)
Number of subjects: 1069
Study 35489363 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (oral 50 mg per day, 4 weeks on followed by 2 weeks off)
Number of subjects: 1069
Study 33477172 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners' estimation of prevalence of non-dialysis chronic kidney disease
Number of subjects: 1130
Study 33477172 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of urine dipstick test for proteinuria diagnosis
Number of subjects: 1130
Study 33477172 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of albumin/creatinine-ratio for proteinuria diagnosis
Number of subjects: 1130
Study 33477172 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment of high blood pressure and diabetes mellitus
Number of subjects: 1130
Study 33477172 — intervention group
Group type: EXPERIMENTAL
Intervention: Competence in treating non-dialysis chronic kidney disease
Number of subjects: 1130
Study 33477172 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of working experience on tool selection
Number of subjects: 1130
Study 33142973 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (TT)
Number of subjects: 0
Study 33142973 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback manikins (FT)
Number of subjects: 0
Study 33142973 — intervention group
Group type: COMPARATOR
Intervention: Mobile phone applications (AP)
Number of subjects: 0
Study 36084276 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan plus cyclophosphamide (BuCy)
Number of subjects: 550
Study 36084276 — intervention group
Group type: COMPARATOR
Intervention: Total body irradiation plus cyclophosphamide (TBI-Cy)
Number of subjects: 550
Study 33942376 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine (active treatment)
Number of subjects: 297
Study 33581174 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg MET409
Number of subjects: 58
Study 33581174 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg MET409
Number of subjects: 58
Study 33581174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 32483272 — intervention group
Group type: EXPERIMENTAL
Intervention: TET1 expression
Number of subjects: 0
Study 35799554 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaSight double-lumen tube (VDLT)
Number of subjects: 100
Study 35799554 — intervention group
Group type: COMPARATOR
Intervention: Conventional double-lumen tube (cDLT)
Number of subjects: 100
Study 34648598 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet (1100 kcal/day, five days/week)
Number of subjects: 50
Study 34648598 — intervention group
Group type: COMPARATOR
Intervention: Control diet (usual Swedish intake)
Number of subjects: 50
Study 32648183 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 0
Study 32648183 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection for rectal cancer
Number of subjects: 0
Study 32648183 — intervention group
Group type: COMPARATOR
Intervention: Robotic technology
Number of subjects: 0
Study 32648183 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study 35911222 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 83
Study 35911222 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 83
Study 32389808 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPP (lifestyle intervention program)
Number of subjects: 0
Study 32389808 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 0
Study 33893936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 101
Study 33893936 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 101
Study 33893936 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of CD36+/CD61+/AV+ MPs
Number of subjects: 101
Study 33893936 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC-curve model for CD36+/CD61+/AV+ MPs
Number of subjects: 101
Study 33893936 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG examination
Number of subjects: 101
Study 32633541 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 119
Study 32633541 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 119
Study 32633541 — intervention group
Group type: EXPERIMENTAL
Intervention: Molindone
Number of subjects: 119
Study 32633541 — intervention group
Group type: EXPERIMENTAL
Intervention: All antipsychotics combined
Number of subjects: 119
Study 32873681 — intervention group
Group type: EXPERIMENTAL
Intervention: (extended) pleurectomy decortication
Number of subjects: 0
Study 32873681 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 35932912 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0
Study 35932912 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 35932912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study 32636444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 100
Study 32636444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 100
Study 35243909 — intervention group
Group type: EXPERIMENTAL
Intervention: Class-based face-to-face body awareness lessons
Number of subjects: 20
Study 35243909 — intervention group
Group type: COMPARATOR
Intervention: Home-based individually performed body awareness lessons
Number of subjects: 20
Study 35557513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group (CDDP 20 pills three times per day)
Number of subjects: 250
Study 35557513 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (10 pills CDDP and 10 pills placebo three times per day)
Number of subjects: 250
Study 33385279 — intervention group
Group type: EXPERIMENTAL
Intervention: TransPrEP intervention
Number of subjects: 89
Study 33385279 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 89
Study 33621406 — intervention group
Group type: COMPARATOR
Intervention: LPR patients
Number of subjects: 89
Study 33621406 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OSAS, LPR, and GERD
Number of subjects: 89
Study 35426736 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular Acupressure (AA) on active points
Number of subjects: 133
Study 35426736 — intervention group
Group type: COMPARATOR
Intervention: Sham Auricular Acupressure (SAA)
Number of subjects: 133
Study 35426736 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular Acupressure (AA)
Number of subjects: 133
Study 33059380 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with 0.5% tetracaine-HCl ophthalmic solution applied three times at 30-second intervals after wound closure
Number of subjects: 50
Study 33059380 — intervention group
Group type: COMPARATOR
Intervention: No topical anaesthesia (control group)
Number of subjects: 50
Study 35144570 — intervention group
Group type: EXPERIMENTAL
Intervention: Inquiry‐Based Stress Reduction counseling session (2 hours weekly for 6 weeks)
Number of subjects: 67
Study 35144570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 67
Study 33244872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) alpha1‐PI[h] therapy (90 or 180 mg/kg weekly for 13 or 26 weeks)
Number of subjects: 76
Study 33244872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) alpha1‐PI[h] therapy
Number of subjects: 76
Study 33244872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 35093007 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA < 3 log10 copies/million PBMC
Number of subjects: 1013
Study 32139400 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor Ailment Service (MAS)
Number of subjects: 894
Study 32139400 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 894
Study 35344808 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Hz low-frequency stimulation of the fornicodorsocommissural tract
Number of subjects: 5
Study 35344808 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hz low-frequency stimulation of the fornicodorsocommissural tract
Number of subjects: 5
Study 35344808 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency stimulation (2Hz or 5Hz)
Number of subjects: 5
Study 32375763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application after rehabilitation
Number of subjects: 740
Study 32375763 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 740
Study 36326771 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral periarterial block (FAB)
Number of subjects: 42
Study 33481300 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised 12-week programme of aerobic and muscle strengthening exercise with Smartband
Number of subjects: 100
Study 33481300 — intervention group
Group type: COMPARATOR
Intervention: Standardized advice about physical activity
Number of subjects: 100
Study 35841457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mongersen (oral antisense oligonucleotide targeting Smad7)
Number of subjects: 0
Study 35841457 — intervention group
Group type: COMPARATOR
Intervention: Mongersen
Number of subjects: 0
Study 32698812 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and Feedback (A&F)
Number of subjects: 0
Study 32698812 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and Feedback plus External Facilitation (A&F + EF)
Number of subjects: 0
Study 32698812 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35077474 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline (1 mg/day)
Number of subjects: 2
Study 35077474 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline (0.5 mg/day)
Number of subjects: 2
Study 35077474 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2
Study 33757474 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cranberry proanthocyanidin extract (2 × 18.5 mg daily, n = 72)
Number of subjects: 145
Study 33757474 — intervention group
Group type: COMPARATOR
Intervention: Low dose cranberry proanthocyanidin extract (2 × 1 mg daily, n = 73)
Number of subjects: 145
Study 33757474 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cranberry proanthocyanidin extract
Number of subjects: 145
Study 32833477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness based cognitive therapy ‐ perinatal depression (MBCT‐PD)
Number of subjects: 74
Study 32833477 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 74
Study 35300902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral nerve block (UGFN)
Number of subjects: 48
Study 35300902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UGFN)
Number of subjects: 48
Study 34405737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oficina da Lembrança (OL) program for 12 weeks
Number of subjects: 64
Study 34405737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study 32461297 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab interval lengthening (every 3 weeks, then every 4 weeks)
Number of subjects: 174
Study 32461297 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab EOW (every other week)
Number of subjects: 174
Study 32461297 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab interval lengthening
Number of subjects: 174
Study 36319057 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenamine hippurate 1 g, two times per day for 6 months
Number of subjects: 400
Study 36319057 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets, two times per day for 6 months
Number of subjects: 400
Study 33109586 — intervention group
Group type: EXPERIMENTAL
Intervention: α-type-1 DC vaccine
Number of subjects: 16
Study 36108648 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic search for pulmonary embolism (PE)
Number of subjects: 0
Study 36108648 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 35130832 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 480
Study 35130832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 32245508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) for 4 weeks in the START block, followed by a switch to active drug for the placebo group.
Number of subjects: 0
Study 32245508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) in the STOP block.
Number of subjects: 0
Study 32245508 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the START block (initially), switched to HCQ after 4 weeks.
Number of subjects: 0
Study 32245508 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the STOP block.
Number of subjects: 0
Study 34521506 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom zirconia abutment with a bonded titanium insert
Number of subjects: 80
Study 34521506 — intervention group
Group type: COMPARATOR
Intervention: Custom titanium abutment
Number of subjects: 80
Study 34845077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyfosy with additional tubal flushing with oil soluble contrast medium (OSCM)
Number of subjects: 12
Study 34845077 — intervention group
Group type: COMPARATOR
Intervention: Hyfosy without additional flushing
Number of subjects: 12
Study 37246674 — intervention group
Group type: EXPERIMENTAL
Intervention: Same Arm Movement Therapy for 8 weeks (45 min supervised sessions 3 times a week and structured independent sessions twice a week)
Number of subjects: 22
Study 37246674 — intervention group
Group type: COMPARATOR
Intervention: Constraint Induced Movement Therapy for 8 weeks (2 hours per day, 5 days a week, with restriction of the non-affected extremity for 10 hours a day)
Number of subjects: 22